Psychopharmacology最新文献

{"title":"Optimizing esketamine administration for postoperative depression: a comprehensive study on laparoscopic bariatric surgery patients.","authors":"Jiabao Dai, Yanfeng Lu, Zhiqing Zou, Zhouquan Wu","doi":"10.1007/s00213-024-06673-y","DOIUrl":"10.1007/s00213-024-06673-y","url":null,"abstract":"<p><strong>Background: </strong>Previous studies have reported conflicting findings regarding the efficacy of esketamine in managing postoperative depression. While the positive effects of subanesthetic doses esketamine have been observed in treatment-resistant depression, the response to this medication in patients experiencing depression following surgery has not been consistent. Building upon the known impact of anesthesia on brain function, we have formulated a hypothesis suggesting that the timing of esketamine administration in relation to anesthesia may significantly affect its efficacy in managing postoperative depression. The aim of this study was to investigate the effect of esketamine administered at different time points before and after anesthesia.</p><p><strong>Methods: </strong>Our randomized, double-blind, controlled study involved 120 patients undergoing laparoscopic bariatric surgery, randomly divided into three groups. Group Post- ESK received an intravenous injection of esketamine at a dose of 0.2 mg/kg after anesthesia induction. Group Pre- ESK received the same esketamine dosage 2 h prior to anesthesia induction. Group Placebo served as the control group and received a 0.9% saline solution after induction. The primary outcome measures of the study were depression scores as measured by Patient Health Questionnaire-9 (PHQ-9) and plasma brain-derived neurotrophic factor (BDNF) levels.</p><p><strong>Results: </strong>On the first postoperative day, the PHQ-9 scores, incidence and severity of postoperative depression in the Pre-ESK group were significantly lower than those in the Post-ESK and placebo groups (P < 0.05). Additionally, plasma BDNF levels in the Pre-ESK group were significantly higher than those in the Post-ESK and placebo groups (P < 0.05). Notably, there was a negative correlation between PHQ-9 scores and plasma BDNF levels.</p><p><strong>Conclusions: </strong>Our study supports the potential for subanesthetic dose esketamine to alleviate postoperative depression symptoms following laparoscopic bariatric surgery, and anesthetic drugs have a significant effect on its efficacy. The use of subanesthetic dose esketamine after anesthesia does not improve postoperative depression symptoms in patients undergoing laparoscopic bariatric surgery, while the use of sub-anesthetic dose esketamine before anesthesia can improve postoperative depression symptoms.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":"285-295"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11774953/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oxytocin effects on socially transmitted food preferences are moderated by familiarity between rats.","authors":"Irina Noguer-Calabús, Sandra Schäble, José Dören, Tobias Kalenscher","doi":"10.1007/s00213-024-06682-x","DOIUrl":"10.1007/s00213-024-06682-x","url":null,"abstract":"<p><strong>Rationale: </strong>In the socially transmitted food preference (STFP) paradigm, rats change their preference for food rewards after socially interacting with a conspecific who has been fed with the originally non-preferred food. Here, we asked if oxytocin (OXT), a neuropeptide known for its role in social affiliation and social behavior, plays a role in STFP. Since OXT's influences on social behavior can be familiarity-dependent, we further asked if OXT effects on STFP are moderated by the familiarity between rats.</p><p><strong>Objectives: </strong>Does OXT modulate rats' socially transmitted food choices in a familiarity-dependent way.</p><p><strong>Methods: </strong>We systemically injected either vehicle, low-dose (0.25 mg/kg) of OXT, or large-dose (1.0 mg/kg) of OXT before social interaction with either a familiar cagemate (in-group) or an unfamiliar conspecific from a different cage (out-group).</p><p><strong>Results: </strong>We found an intergroup bias in STFP: vehicle-treated rats showed larger socially transmitted changes in food preference in the out-group than the in-group condition. OXT modulated STFP in a familiarity-dependent way: OXT prevented the increase in the consumption of the non-preferred food in the out-group, and decreased the consumption of the preferred food in the in-group. These effects were dose-dependent and observed under acute OXT action, but also on the subsequent day when acute OXT effects dissipated, suggesting long-lasting social learning effects of OXT. Additional analyses suggest that the familiarity and dose-dependent effects of OXT on STFP cannot be attributed to OXT's anorexic actions or differences in the duration of the social interactions.</p><p><strong>Conclusions: </strong>OXT modulates STFP in a familiarity-dependent way.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":"361-372"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142352688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pituitary adenylate cyclase-activating polypeptide (PACAP)⁺ cells in the paraventricular nucleus of the thalamus: relationship with binge-type eating in male and female mice.","authors":"Genevieve R Curtis, Brody A Carpenter, Breanne E Pirino, Annie Hawks, George Li, Jessica R Barson","doi":"10.1007/s00213-024-06692-9","DOIUrl":"10.1007/s00213-024-06692-9","url":null,"abstract":"<p><strong>Rationale: </strong>Both the paraventricular nucleus of the thalamus (PVT) and the neuropeptide, pituitary adenylate cyclase-activating polypeptide (PACAP), are thought to be involved in food intake. Importantly, PACAP is expressed in cells of the PVT.</p><p><strong>Objectives: </strong>To determine if PACAP in cells of the PVT might mediate some of the involvement of the PVT with palatable food intake.</p><p><strong>Methods: </strong>In male and female C57BL/6 J mice and PACAP-Cre transgenic mice on a C57BL/6 J background, limited access to Milk Chocolate Ensure Plus® was used to establish a model of binge-type eating. Next, using quantitative real-time PCR, gene expression of PACAP in the PVT was measured in relation to this binge-type eating. Finally, using chemogenetics in PACAP-Cre transgenic mice, the effect of activation of PVT PACAP⁺ cells on binge-type eating was determined.</p><p><strong>Results: </strong>Males and females both engaged in binge-type eating with Ensure, although females engaged in this behavior to a greater degree than males. While females also had a higher baseline level of PVT PACAP mRNA than males, only males showed an increase in levels of PACAP after a history of exposure to Ensure, and only males showed a reduction in levels of PACAP immediately prior to a binge session. Conversely, activation of PACAP⁺ cells in the PVT reduced binge-type eating of Ensure, specifically in male mice.</p><p><strong>Conclusions: </strong>The present findings indicate that PVT PACAP⁺ cells influence and are influenced by binge-type eating. Thus, PACAP in the PVT might mediate some of the known involvement of the PVT with palatable food intake.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":"413-426"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11774677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142352689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Choice of alcohol over a natural reward: an experimental study in light and heavy social drinkers.","authors":"Hanna Karlsson, Sarah Mcntyre, Sarah Gustavson, David Andersson, Ilona Szczot, Markus Heilig, Irene Perini","doi":"10.1007/s00213-024-06679-6","DOIUrl":"10.1007/s00213-024-06679-6","url":null,"abstract":"<p><strong>Rationale & objectives: </strong>A core symptom of alcohol use disorder (AUD) is a progressively increased choice of alcohol over alternative rewards despite negative consequences. Here, we investigated choice between personalized alcohol vs. natural rewards in a laboratory setting, and compared this behavior between non-treatment-seeking heavy drinkers and light social drinkers.</p><p><strong>Methods: </strong>30 light social drinkers (15 men drinking < 15 drinks/week and 15 women drinking < 10 drinks/week) and 30 heavy, non-treatment-seeking drinkers (drinking more than these levels; 15 women). In the Concurrent Choice Alcohol Food (CCAF) task, participants chose between individually tailored images of alcohol and snack rewards and collected points towards the respective reward. To assess cost sensitivity, points associated to the images varied so that they favored alcohol or snack, or were equal, creating three relative point levels.</p><p><strong>Results: </strong>Choice preference for alcohol was strongly correlated with Alcohol Use Disorder Identification Test (AUDIT) scores, supporting the external validity of the choice procedure. Compared to light drinkers, heavy drinkers showed increased choice preference for alcohol, as indicated by a between-group difference in points of subjective equality, a metric that quantifies the relative point level at which alcohol and snacks were equally likely to be chosen. In both groups, choice preference strongly depended on the relative point level of alcohol compared to snacks, suggesting that responding for alcohol in heavy drinkers was sensitive to costs.</p><p><strong>Conclusions: </strong>Our results replicate previous findings of a relationship between self-reported alcohol use and choice preference for alcohol. We also found that choice behavior was strongly dependent on relative cost of alcohol in both groups, although price sensitivity was lower in heavy compared to light drinkers. An increased choice preference for alcohol in heavy drinkers suggests that they attribute a higher relative reinforcing value to alcohol compared to natural rewards.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":"327-336"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142366353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of agomelatine on sleep disorders and lateral habenula neuronal activity in chronic restraint stress depression model mice.","authors":"Zhuojun Kang, Zhenzhen Zheng, Wenli Guo","doi":"10.1007/s00213-024-06681-y","DOIUrl":"10.1007/s00213-024-06681-y","url":null,"abstract":"<p><strong>Background: </strong>Sleep disorders (SD) are one of the common manifestations of depression patients. This article aimed to explore the effect of Agomelatine (Ago) on SD in chronic restraint stress (CRS) depression model mice and its effect on the activity of neurons in the lateral habenula (LHb).</p><p><strong>Methods: </strong>30 C57BL/6 J mice were divided into normal (C57BL/6 J) group, CRS group, and Ago group. CRS experiment was used to establish the depression model, and Ago was used to treat CRS mice. Based on behavioral tests in mice and electrophysiology record, SD and LHb neuron activity were assessed. The expression levels of brain-derived neurotrophic factor (BDNF) and nuclear phosphoprotein (c-Fos) in LHb were detected by Western blot (WB).</p><p><strong>Results: </strong>As against the CRS group, the Ago group had a reduction in the immobility time during forced swimming training and an increase in the preference for sucrose in the sucrose preference test; The expression levels of c-Fos and BDNF proteins in the LHb neurons of the Ago group mice were lower than those in the CRS group (P < 0.05), and the values approached the levels of the normal control group. In both dark and light environments, the rapid eye movement (REM) sleep duration of the CRS group mice was significantly longer than that of the normal control group (P < 0.05).</p><p><strong>Conclusion: </strong>It was concluded that Ago may intervene in the depressive-like behavior and overall sleep patterns of CRS depression model mice by regulating the activity of LHb neurons and inhibiting the neuroinflammatory process. This provides a potential drug target for the development of new treatment strategies for depression.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":"353-360"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The ultrasonic vocalization (USV) syllable profile during neonatal opioid withdrawal and a kappa opioid receptor component to increased USV emissions in female mice.","authors":"Kelly K Wingfield, Teodora Misic, Kaahini Jain, Carly S McDermott, Nalia M Abney, Kayla T Richardson, Mia B Rubman, Jacob A Beierle, Sophia A Miracle, Emma J Sandago, Britahny M Baskin, William B Lynch, Kristyn N Borrelli, Emily J Yao, Elisha M Wachman, Camron D Bryant","doi":"10.1007/s00213-024-06694-7","DOIUrl":"10.1007/s00213-024-06694-7","url":null,"abstract":"<p><strong>Rationale: </strong>Opioid use during pregnancy can lead to negative infant health outcomes, including neonatal opioid withdrawal syndrome (NOWS). NOWS comprises gastrointestinal, autonomic nervous system, and neurological dysfunction that manifest during spontaneous withdrawal. Variability in NOWS severity necessitates a more individualized treatment approach. Ultrasonic vocalizations (USVs) in neonatal mice are emitted in isolation as a stress response and are increased during opioid withdrawal, thus modeling a negative affective state that can be utilized to test new treatments.</p><p><strong>Objectives: </strong>We sought to identify the behavioral and USV profile, brainstem transcriptomic adaptations, and role of kappa opioid receptors in USVs during neonatal opioid withdrawal.</p><p><strong>Methods: </strong>We employed a third trimester-approximate opioid exposure model, where neonatal inbred FVB/NJ pups were injected twice-daily with morphine (10mg/kg, s.c.) or saline (0.9%, 20 ul/g, s.c.) from postnatal day(P) 1 to P14. This protocol induces reduced weight gain, hypothermia, thermal hyperalgesia, and increased USVs during spontaneous morphine withdrawal.</p><p><strong>Results: </strong>On P14, there were increased USV emissions and altered USV syllables during withdrawal, including an increase in Complex 3 syllables in FVB/NJ females (but not males). Brainstem bulk mRNA sequencing revealed an upregulation of the kappa opioid receptor (Oprk1), which contributes to withdrawal-induced dysphoria. The kappa opioid receptor (KOR) antagonist, nor-BNI (30 mg/kg, s.c.), significantly reduced USVs in FVB/NJ females, but not males during spontaneous morphine withdrawal. Furthermore, the KOR agonist, U50,488h (0.625 mg/kg, s.c.), was sufficient to increase USVs on P10 (both sexes) and P14 (females only) in FVB/NJ mice.</p><p><strong>Conclusions: </strong>We identified an elevated USV syllable, Complex 3, and a female-specific recruitment of the dynorphin/KOR system in increased USVs associated with neonatal opioid withdrawal severity.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":"427-447"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142352690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of nightly use of 150 mg cannabidiol on daytime neurocognitive performance in primary insomnia: a randomized controlled pilot trial.","authors":"Andrea J Narayan, Amie C Hayley, Sarah Rose, Lauren Di Natale, Luke A Downey","doi":"10.1007/s00213-024-06674-x","DOIUrl":"10.1007/s00213-024-06674-x","url":null,"abstract":"<p><strong>Rationale: </strong>Cannabidiol (CBD) is increasingly used as a sleep aid for insomnia; yet neurocognitive and subjective state effects following daily therapeutic use are unclear.</p><p><strong>Objectives: </strong>To measure the effect of daily CBD use on neurocognitive performance and daily subjective mood in a population with primary insomnia.</p><p><strong>Methods: </strong>This study used a randomized, placebo-controlled, parallel design incorporating a single-blind placebo run-in week followed by a two-week double-blind dosing period, during which participants consumed 150 mg CBD (N = 15) or placebo (N = 15) sublingually 60-minutes daily before bed. Attention, executive function, reasoning, information processing, working and episodic memory were assessed using the CogPro system at the beginning of the placebo run-in, after 1-week and 2-weeks of dosing. Subjective states using visual analogue scales and side effects were recorded daily.</p><p><strong>Results: </strong>Cognitive performance was unaffected by nightly CBD supplementation (all p > 0.05). From baseline to trial conclusion, those receiving CBD reported greater experience of calmness, clear-headedness, coordination and were more likely to report side-effects of dry mouth relative to placebo (all p < 0.05).</p><p><strong>Conclusions: </strong>Relative to placebo, daytime cognitive functioning following nightly supplementation as a therapeutic aid for primary insomnia was preserved under trial conditions. Results suggested an overall favourable safety profile, with larger controlled trials and thorough analyses of varying insomnia phenotypes necessary to corroborate these findings.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":"297-308"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11774964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141996335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute analgesic effect of nicotine vaping using three experimental pain induction tasks: a randomized, placebo-controlled laboratory study.","authors":"Michael P Bremmer, Michael B Paladino, Alana M Campbell, Kai Xia, Robert Tarran, Christian S Hendershot, Susan S Girdler","doi":"10.1007/s00213-024-06669-8","DOIUrl":"10.1007/s00213-024-06669-8","url":null,"abstract":"<p><strong>Rationale: </strong>Pain and nicotine use are co-occurring conditions with a significant impact on health. Experimental evidence supports an acute analgesic effect of nicotine which may reinforce nicotine use among those with chronic pain. Evidence for nicotine analgesia have primarily been gathered in combustible cigarette users and have not been extended to electronic nicotine delivery systems (ENDS or vaping). Furthermore, the mechanisms of nicotine analgesia in humans are not well understood.</p><p><strong>Objectives: </strong>Assess the effect of acute vaped nicotine on subjective and behavioral indices of pain sensitivity using three tasks designed to probe distinct mechanisms of analgesia.</p><p><strong>Methods: </strong>This study recruited ENDS users (N = 86) to undergo a paced vaping protocol followed by pain tasks in counterbalanced order. Across four sessions, participants vaped e-liquid containing nicotine or placebo, and flavor or no-flavor in a 2 × 2 within-subject design. Assessments included cold pressor, submaximal effort tourniquet to induce ischemic pain, and temporal summation of heat pain, an index of central sensitization.</p><p><strong>Results: </strong>Compared to placebo, nicotine increased cold pressor pain tolerance (η_p² = 0.031), ischemic pain threshold (η_p² = 0.073) and tolerance (η_p² = 0.056) but had no effect on temporal summation of pain. Flavor did not affect pain sensitivity. Females reported greater ischemic pain sensitivity (η_p² = 0.027) and greater reductions in craving (η_p² = 0.086).</p><p><strong>Conclusions: </strong>Consistent with research from tobacco smoking, analgesia may be reinforcing and contribute to nicotine dependence among ENDS users. More research on sex differences is warranted.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":"235-245"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141907579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of lorazepam on saccadic eye movements - evidence from prosaccade and free viewing tasks.","authors":"Philine M Baumert, Kaja Faßbender, Maximilian W M Wintergerst, Jan H Terheyden, Behrem Aslan, Tom Foulsham, Wolf Harmening, Ulrich Ettinger","doi":"10.1007/s00213-024-06672-z","DOIUrl":"10.1007/s00213-024-06672-z","url":null,"abstract":"<p><strong>Rationale: </strong>Peak velocities of saccadic eye movements are reduced after benzodiazepine administration. Even though this is an established effect, past research has only examined it in horizontal prosaccade tasks.</p><p><strong>Objectives: </strong>The spectrum of saccadic eye movements, however, is much larger. Therefore, we aimed to make a first attempt at filling this research gap by testing benzodiazepine effects on saccades under different experimental task conditions.</p><p><strong>Methods: </strong>1 mg lorazepam or placebo was administered (within-subjects, double-blind, in randomised order) to n = 30 healthy adults. Participants performed an extended version of the prosaccade task, including vertical saccade directions and different stimulus eccentricities, as well as a free viewing task.</p><p><strong>Results: </strong>Results from the prosaccade task confirmed established effects of benzodiazepines as well as saccade direction on saccadic parameters but additionally showed that the drug effect on peak velocity was independent of saccade direction. Remarkably, in the free viewing task peak velocities as well as other saccade parameters were unaffected by lorazepam. Furthermore, exploration patterns during free viewing did not change under lorazepam.</p><p><strong>Conclusions: </strong>Overall, our findings further consolidate the peak velocity of prosaccades as a biomarker of sedation. Additionally, we suggest that sedative effects of low doses of benzodiazepines may be compensated in tasks that more closely resemble natural eye movement behaviour, possibly due to the lack of time constraints or via neurophysiological processes related to volition.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":"271-284"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabidiol enhances socially transmitted food preference: a role of acetylcholine in the mouse basal forebrain.","authors":"Chih-Yu Chang, Wen Dai, Sherry Shu-Jung Hu","doi":"10.1007/s00213-024-06670-1","DOIUrl":"10.1007/s00213-024-06670-1","url":null,"abstract":"<p><strong>Rationale and objective: </strong>Rodents acquire food information from their conspecifics and display a preference for the conspecifics' consumed food. This social learning of food information from others promotes the survival of a species, and it is introduced as the socially transmitted food preference (STFP) task. The cholinergic system in the basal forebrain plays a role in the acquisition of STFP. Cannabidiol (CBD), one of the most abundant phytocannabinoids, exerts its therapeutic potential for cognitive deficits through versatile mechanisms of action, including its interaction with the cholinergic system. We hypothesize a positive relationship between CBD and STFP because acetylcholine (ACh) is involved in STFP, and CBD increases the ACh levels in the basal forebrain.</p><p><strong>Materials and methods: </strong>Male C57BL/6J mice were trained to acquire the STFP task. We examined whether CBD affects STFP memory by administering CBD (20 mg/kg, i.p.) before the STFP social training. The involvement of cholinergic system in CBD's effect on STFP was examined by knockdown of brain acetylcholinesterase (AChE), applying a nonselective muscarinic antagonist SCO (3 mg/kg, i.p.) before CBD treatment, and measuring the basal forebrain ACh levels in the CBD-treated mice.</p><p><strong>Results: </strong>We first showed that CBD enhanced STFP memory. Knockdown of brain AChE also enhanced STFP memory, which mimicked CBD's effect on STFP. SCO blocked CBD's memory-enhancing effect on STFP. Our most significant finding is that the basal forebrain ACh levels in the CBD-treated mice, but not their control counterparts, were positively correlated with mice's STFP memory performance.</p><p><strong>Conclusion: </strong>This study indicates that CBD enhances STFP memory in mice. Specifically, those which respond to CBD by increasing the muscarinic-mediated ACh signaling perform better in their STFP memory.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":"247-269"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}